Author:
Lee Jin Kyung,Leslie Elaine M.,Zamek-Gliszczynski Maciej J.,Brouwer Kim L.R.
Reference57 articles.
1. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype;Beumer;Invest. New Drugs,2007
2. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer;Beumer;Cancer Chemother. Pharmacol.,2007
3. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer;Beumer;Invest. New Drugs,2005
4. A phase II study of ET-743/trabectedin (Yondelis) for patients with advanced gastrointestinal stromal tumours;Blay;Eur. J. Cancer,2004
5. In-vitro cytotoxicity of ET-743 (trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction;Brandon;Anticancer Drugs,2005
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献